Baker Bros. Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Baker Bros. Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-673,908	Closed	-$11.3M	–	125
2020 Q2	$11.3M	Hold	673,908	–	–	0.05%	57
2020 Q1	$9.72M	Hold	673,908	–	–	0.06%	50
2019 Q4	$22.6M	Hold	673,908	–	–	0.12%	44
2019 Q3	$14.1M	Hold	673,908	–	–	0.1%	45
2019 Q2	$14M	Hold	673,908	–	–	0.1%	45
2019 Q1	$15.1M	Hold	673,908	–	–	0.1%	41
2018 Q4	$16.1M	Hold	673,908	–	–	0.13%	37
2018 Q3	$18.4M	Hold	673,908	–	–	0.12%	43
2018 Q2	$18.1M	Hold	673,908	–	–	0.14%	44
2018 Q1	$21.4M	Hold	673,908	–	–	0.18%	42
2017 Q4	$25.5M	Hold	673,908	–	–	0.22%	39
2017 Q3	$16.7M	Hold	673,908	–	–	0.14%	42
2017 Q2	$13.9M	Hold	673,908	–	–	0.12%	41
2017 Q1	$14.6M	Hold	673,908	–	–	0.12%	39
2016 Q4	$13.8M	Hold	673,908	–	–	0.14%	41
2016 Q3	$10.1M	Hold	673,908	–	–	0.09%	54
2016 Q2	$7.29M	Buy	673,908 +423,908	+170%	+$5.76M	0.08%	62
2016 Q1	$3.39M	Hold	250,000	–	–	0.04%	82
2015 Q4	$4.61M	Hold	250,000	–	–	0.04%	80
2015 Q3	$6.33M	Buy	+250,000	New	+$5.84M	0.06%	71

Other funds holding AIMT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Baker Bros. Advisors's AIMT Position: Q3 2020 in Review

Baker Bros. Advisors sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 673,908 shares — an estimated $11.3M sold.

Baker Bros. Advisors first reported a position in AIMT in Q3 2015 and held it in 20 quarters. The position peaked at $25.5M in Q4 2017. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

Baker Bros. Advisors reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
Baker Bros. Advisors sold 673,908 Aimmune Therapeutics shares in Q3 2020, an estimated $11.3M.
Baker Bros. Advisors first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 20 quarters.
Baker Bros. Advisors's Aimmune Therapeutics position peaked at $25.5M in Q4 2017.
188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Baker Bros. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.